Drug intelligence / Profile preview

SKM-301

Development stage: Unknown
Lead developer: Skymab Biotherapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

SKM-301 is an antibody-drug conjugate (ADC) under development by Skymab Biotherapeutics. It is currently in the discovery phase and is being investigated for the treatment of neoplasms, specifically solid tumors. The precise molecular target, payload, and linker details have not been disclosed publicly as of June 2025. The drug represents a targeted therapy approach, aiming to deliver cytotoxic agents directly to tumor cells via an antibody specific for a tumor-associated antigen[1][2].

Beyond the preview

Go deeper on SKM-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKM-301.

Explore the full profile